CLDX - Celldex Therapeutics Inc Stock Price, Fair Value and News

39.39USD-0.72 (-1.80%)Market Closed

Market Summary

USD39.39-0.72

Market Closed

-1.80%

CLDX Stock Price

View Fullscreen

CLDX RSI Chart

CLDX Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-17.92

Price/Sales (Trailing)

197.99

EV/EBITDA

-17.93

Price/Free Cashflow

-21.47

CLDX Price/Sales (Trailing)

CLDX Profitability

EBT Margin

-1078.54%

Return on Equity

-17.27%

Return on Assets

-16.67%

Free Cashflow Yield

-4.66%

CLDX Fundamentals

CLDX Revenue

Revenue (TTM)

13.1M

Rev. Growth (Yr)

209.08%

Rev. Growth (Qtr)

45.05%

CLDX Earnings

Earnings (TTM)

-144.9M

Earnings Growth (Yr)

-11.71%

Earnings Growth (Qtr)

24.26%

Breaking Down CLDX Revenue

Last 7 days

-6.7%

Last 30 days

0.4%

Last 90 days

8.6%

Trailing 12 Months

15.0%

How does CLDX drawdown profile look like?

CLDX Financial Health

Current Ratio

31.77

CLDX Investor Care

Shares Dilution (1Y)

39.49%

Diluted EPS (TTM)

-2.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	5.8M	8.1M	10.2M	13.1M
2022	1.1M	1.7M	2.3M	2.9M
2021	5.4M	8.6M	8.1M	505.0K
2020	4.9M	4.4M	4.5M	7.4M
2019	6.9M	4.8M	4.5M	3.6M
2018	15.3M	14.2M	11.2M	9.5M
2017	7.0M	9.5M	11.2M	12.7M
2016	6.3M	5.5M	6.7M	6.8M
2015	3.7M	5.2M	5.2M	5.5M
2014	2.1M	2.6M	2.7M	3.6M
2013	11.2M	9.3M	7.1M	4.1M
2012	9.2M	9.2M	10.0M	11.2M
2011	45.6M	44.6M	44.6M	9.3M
2010	0	25.7M	36.3M	46.8M
2009	0	0	0	15.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Celldex Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 13, 2024	jimenez freddy a.	acquired	93,162	3.85512	24,166	svp & general counsel
Jan 02, 2024	martin samuel bates	acquired	29,885	2.78	10,750	svp and cfo
Dec 07, 2022	keler tibor	acquired	46,870	2.78	16,860	executive vp & cso
Dec 07, 2022	keler tibor	sold	-622,611	36.9283	-16,860	executive vp & cso
Aug 18, 2022	cavanaugh sarah	sold	-49,289	36.3757	-1,355	svp of corp affairs & admin.
Aug 18, 2022	cavanaugh sarah	acquired	12,217	9.0165	1,355	svp of corp affairs & admin.
Aug 17, 2022	cavanaugh sarah	acquired	87,047	2.78	31,312	svp of corp affairs & admin.
Aug 17, 2022	cavanaugh sarah	sold	-1,150,220	36.7342	-31,312	svp of corp affairs & admin.
Aug 17, 2022	young diane c.	acquired	319,170	4.98703	64,000	svp, chief medical officer
Aug 17, 2022	young diane c.	sold	-708,715	37.3008	-19,000	svp, chief medical officer

Which funds bought or sold CLDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	FIRST TRUST ADVISORS LP	added	504	2,474,900	2,933,490	-%
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-525,000	-	-%
May 13, 2024	Ameritas Investment Partners, Inc.	added	34.27	77,059	260,130	0.01%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	26.51	15,025,400	59,370,400	-%
May 13, 2024	Rafferty Asset Management, LLC	added	29.33	2,163,650	8,033,690	0.03%
May 13, 2024	EAM Investors, LLC	new	-	2,942,730	2,942,730	0.46%
May 13, 2024	Nuveen Asset Management, LLC	added	204	10,683,800	15,490,400	-%
May 13, 2024	UBS Group AG	added	62.15	4,489,000	10,758,900	-%
May 13, 2024	Creative Planning	reduced	-78.69	-712,811	207,499	-%
May 13, 2024	STRS OHIO	added	118	140,000	247,000	-%

Are Funds Buying or Selling CLDX?

Are funds buying CLDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLDX

No. of Funds

Unveiling Celldex Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	kynam capital management, lp	5.5%	3,005,904	SC 13G
Feb 14, 2024	point72 asset management, l.p.	5.0%	2,756,122	SC 13G/A
Feb 14, 2024	rtw investments, lp	6.3%	3,463,201	SC 13G/A
Feb 14, 2024	eventide asset management, llc	6.64%	3,630,013	SC 13G
Feb 13, 2024	polar capital holdings plc	5.73%	3,135,871	SC 13G
Feb 13, 2024	vanguard group inc	5.57%	3,046,331	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	11.84%	6,476,561	SC 13G/A
Jan 26, 2024	blackrock inc.	6.7%	3,675,692	SC 13G/A
Nov 20, 2023	point72 asset management, l.p.	6.6%	3,622,136	SC 13G

Recent SEC filings of Celldex Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Mar 01, 2024	424B5	Prospectus Filed
Mar 01, 2024	8-K	Current Report
Feb 28, 2024	424B5	Prospectus Filed
Feb 26, 2024	8-K	Current Report
Feb 26, 2024	10-K	Annual Report
Feb 26, 2024	424B5	Prospectus Filed

Peers (Alternatives to Celldex Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.93	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.99	9.55	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.4	14.64	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

Celldex Therapeutics Inc News

Latest updates

Celldex Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	4,321,000	2,979,000	2,703,000	3,110,000	1,398,000	912,000	392,000	207,000	179,500	152,000	3,480,000	685,000	3,786,000	668,000	236,000	2,728,000	887,000	546,000	715,000	1,425,000
Costs and Expenses	-21.2%	40,764,000	51,758,000	42,756,000	33,473,000	33,438,000	29,498,000	28,103,000	36,559,000	23,431,000	20,673,500	20,977,000	16,920,000	17,324,000	28,566,000	15,010,000	11,601,000	15,595,000	13,876,000	12,390,000	12,972,000	19,366,000
S&GA Expenses	-100.0%	-	8,832,000	8,221,000	7,221,000	6,640,000	6,599,000	6,531,000	7,154,000	6,911,000	6,240,500	5,821,000	4,306,000	4,121,000	3,622,500	3,640,000	3,528,000	3,666,000	3,219,000	3,403,000	3,908,000	4,896,000
R&D Expenses	4.1%	31,661,000	30,426,000	34,535,000	26,252,000	26,798,000	22,899,000	21,572,000	20,731,000	17,056,000	14,678,000	13,557,000	12,356,000	12,720,000	10,425,500	10,708,000	9,705,000	11,695,000	10,339,000	11,101,000	10,081,000	11,151,000
EBITDA Margin	0.0%	-10.55	-10.56	-10.65	-13.37	-18.68	-37.30	-44.22	-56.16	-66.20	-132	-8.57	-7.30	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-227,000	-	-	900,000	-	-200,000	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-26,487,000	-26,784,000	-36,004,000	-23,050,000	-20,148,000	-20,679,000	-13,373,000	-16,538,000	-22,839,000	-14,224,000	-11,259,000	-	-10,447,000	-11,413,000	-11,779,000	-17,239,000
EBT Margin	0%	-10.79	-10.79	-11.02	-13.83	-19.33	-38.61	-45.92	-58.51	-69.85	-140	-9.06	-7.77	-	-	-	-	-	-	-	-	-
Net Income	24.3%	-32,800,000	-43,306,000	-38,260,000	-30,502,000	-29,361,000	-26,487,000	-26,784,000	-36,004,000	-23,050,000	-20,148,000	-20,452,000	-13,373,000	-16,538,000	-21,900,000	-14,224,000	-11,031,000	-12,625,000	-10,447,000	-11,413,000	-11,779,000	-17,239,000
Net Income Margin	-2.4%	-11.05	-10.79	-12.23	-13.93	-20.41	-38.61	-45.92	-58.38	-69.64	-139	-8.92	-7.66	-	-	-	-	-	-	-	-	-
Free Cashflow	-23.3%	-40,944,000	-33,199,000	-19,115,000	-27,641,000	-29,154,000	-21,997,000	-35,537,000	-22,917,000	-25,109,000	-14,877,000	-16,557,000	-12,073,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	86.6%	869	466	280	299	325	353	369	403	424	445	460	205	219	236	256	261	113	123	132	142	148
Current Assets	93.5%	835	432	246	265	290	318	335	368	391	411	427	168	181	198	203	209	56.00	67.00	75.00	84.00	89.00
Cash Equivalents	230.5%	115	35.00	21.00	28.00	54.00	29.00	19.00	28.00	25.00	39.00	72.00	43.00	69.00	44.00	18.00	68.00	23.00	11.00	17.00	20.00	32.00
Net PPE	0.0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	4.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	5.00
Liabilities	-17.1%	30.00	36.00	34.00	22.00	22.00	27.00	24.00	38.00	26.00	25.00	23.00	22.00	25.00	26.00	26.00	23.00	29.00	29.00	30.00	33.00	35.00
Current Liabilities	-15.5%	26.00	31.00	28.00	16.00	15.00	19.00	16.00	30.00	15.00	17.00	14.00	14.00	17.00	14.00	12.00	11.00	11.00	12.00	12.00	12.00	12.00
Shareholder's Equity	95.4%	839	429	247	278	303	326	345	365	398	419	437	182	194	209	230	238	84.00	94.00	101	110	113
Retained Earnings	-2.3%	-1,430	-1,397	-1,354	-1,315	-1,285	-1,255	-1,229	-1,202	-1,166	-1,143	-1,123	-1,103	-1,089	-1,073	-1,051	-1,036	-1,025	-1,013	-1,002	-991	-979
Additional Paid-In Capital	24.3%	2,266	1,823	1,599	1,591	1,586	1,581	1,575	1,568	1,565	1,561	1,558	1,283	1,281	1,280	1,279	1,273	1,107	1,105	1,102	1,098	1,090
Shares Outstanding	17.9%	66.00	56.00	47.00	47.00	47.00	47.00	47.00	47.00	47.00	47.00	42.00	40.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,600	-	-	-	1,300	-	-	-	1,300	-	-	-	507	-	-	-	40.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-24.8%	-40,600	-32,533	-18,958	-27,231	-28,569	-21,762	-35,192	-22,244	-24,534	-14,523	-16,372	-11,930	-18,084	-5,211	-11,861	-11,222	-12,110	-11,000	-11,140	-11,042	-13,233
Share Based Compensation	-0.1%	7,202	7,212	7,121	5,217	4,340	4,508	4,496	3,454	3,153	3,140	3,029	1,509	1,275	1,257	1,250	721	687	687	707	1,464	1,693
Cashflow From Investing	-84.2%	-315,211	-171,161	11,646	1,164	52,569	31,213	23,068	25,281	10,380	-18,944	-226,787	-13,912	43,487	30,852	-42,506	-108,529	21,965	3,224	5,519	-7,959	16,296
Cashflow From Financing	100.6%	436,112	217,374	257	133	694	1,395	2,306	71.00	304	426	271,897	-25.00	74.00	44.00	4,491	165,054	1,637	2,422	2,463	7,212	4,160

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CLDX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 156	$ 967
Operating expenses:
Research and development	31,661	26,798
General and administrative	9,103	6,640
Total operating expenses	40,764	33,438
Operating loss	(40,608)	(32,471)
Investment and other income, net	7,800	3,110
Net loss	$ (32,808)	$ (29,361)
Basic net loss per common share (in dollars per share)	$ (0.56)	$ (0.62)
Diluted net loss per common share (in dollars per share)	$ (0.56)	$ (0.62)
Shares used in calculating basic net loss per share (in shares)	58,871	47,214
Shares used in calculating diluted net loss per share (in shares)	58,871	47,214
Comprehensive loss:
Net loss	$ (32,808)	$ (29,361)
Other comprehensive income (loss):
Unrealized (loss) gain on marketable securities	(1,064)	863
Comprehensive loss	(33,872)	(28,498)
Product development and licensing agreements
Revenues:
Total revenues	2
Contracts and grants
Revenues:
Total revenues	$ 154	$ 967

CLDX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 115,077	$ 34,814
Marketable securities	708,769	388,784
Accounts and other receivables	2,671	2,628
Prepaid and other current assets	8,807	5,467
Total current assets	835,324	431,693
Property and equipment, net	4,061	4,060
Operating lease right-of-use assets, net	2,165	2,577
Intangible assets	27,190	27,190
Other assets	107	107
Total assets	868,847	465,627
Current liabilities:
Accounts payable	3,234	3,494
Accrued expenses	17,536	22,029
Current portion of operating lease liabilities	1,644	1,614
Current portion of other long-term liabilities	3,877	3,988
Total current liabilities	26,291	31,125
Long-term portion of operating lease liabilities	470	928
Other long-term liabilities	3,473	4,403
Total liabilities	30,234	36,456
Commitments and contingent liabilities
Stockholders' equity:
Convertible preferred stock, $.01 par value; 3,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $.001 par value; 297,000,000 shares authorized; 65,910,548 and 55,883,377 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	66	56
Additional paid-in capital	2,266,472	1,823,168
Accumulated other comprehensive income	2,244	3,308
Accumulated deficit	(1,430,169)	(1,397,361)
Total stockholders' equity	838,613	429,171
Total liabilities and stockholders' equity	$ 868,847	$ 465,627

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

CEO	Mr. Anthony S. Marucci M.B.A.
WEBSITE	celldex.com
INDUSTRY	Biotechnology
EMPLOYEES	148

Celldex Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Celldex Therapeutics Inc? What does CLDX stand for in stocks?

CLDX is the stock ticker symbol of Celldex Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Celldex Therapeutics Inc (CLDX)?

As of Tue May 14 2024, market cap of Celldex Therapeutics Inc is 2.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLDX stock?

You can check CLDX's fair value in chart for subscribers.

What is the fair value of CLDX stock?

You can check CLDX's fair value in chart for subscribers. The fair value of Celldex Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Celldex Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Celldex Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CLDX is over valued or under valued. Whether Celldex Therapeutics Inc is cheap or expensive depends on the assumptions which impact Celldex Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLDX.

What is Celldex Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, CLDX's PE ratio (Price to Earnings) is -17.92 and Price to Sales (PS) ratio is 197.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLDX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Celldex Therapeutics Inc's stock?

In the past 10 years, Celldex Therapeutics Inc has provided -0.15 (multiply by 100 for percentage) rate of return.